HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Erickson, A. L. Articles by Walker, C. M. Search for Related Content PubMed PubMed Citation Articles by Erickson, A. L. Articles by Walker, C. M. Agricola Articles by Erickson, A. L. Articles by Walker, C. M.

Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans

Chiron Corporation, 4560 Horton Street, Emeryville, California 94608, U.S.A.

Cytotoxic T lymphocyte (CTL) responses to vaccinia virus (VV) were studied in human subjects receiving smallpox vaccine by dermal scarification. After in vitro restimulation with VV, peripheral blood mononuclear cells (PBMCs) from three of six vaccinated subjects killed virus-infected target cells. VV-specific, HLA-restricted CTL activity was mediated primarily by CD8⁺ cells, although low levels of lytic activity by CD4⁺ cells were observed in some experiments. Two of the three responders had no history of exposure to VV prior to vaccination, whereas all three non-responders were vaccinated against smallpox during childhood. PBMCs from an additional three subjects who had received smallpox vaccine at least 20 years previously were negative for CTL activity. These data suggest that the duration of memory CTL populations against VV in the peripheral blood is limited, and that pre-existing immunity to VV may interfere with boosting of the CTL response upon revaccination.

Received 24 July 1992; accepted 18 November 1992.

This article has been cited by other articles:

				A. U. Bielinska, A. A. Chepurnov, J. J. Landers, K. W. Janczak, T. S. Chepurnova, G. D. Luker, and J. R. Baker Jr. A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine Clin. Vaccine Immunol., February 1, 2008; 15(2): 348 - 358. [Abstract] [Full Text] [PDF]

				J. C. Ramírez, M. M. Gherardi, D. Rodríguez, and M. Esteban Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector J. Virol., August 15, 2000; 74(16): 7651 - 7655. [Abstract] [Full Text]